Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in breast cancer
- Trial result
Breast cancer
Sacituzumab govitecan (TROP2 ADC) trends toward longer PFS vs chemo in HER2 IHC0 HR+/HER2− mBC (ASCENT-07 subgroup)
Sacituzumab govitecan (SG; a TROP2-directed antibody–drug conjugate delivering SN-38) was compared with chemotherapy treatment of physician’s choice (TPC: capecitabine, paclitaxel, or nab-paclitaxel) in the Phase 3…
NCT05840211 - Trial result
Breast cancer
Zeta-BC-003 (p21-pathway intratumoral biomaterial) drives CT/MRI lytic defect shrinkage and 0 SREs in MBC bone mets
Zeta-BC-003 is a first-in-class intratumoral injectable biomaterial infused with N-allyl noroxymorphone, designed to activate the p21 pathway to promote bone healing alongside local tumor control. In the open-label…
NCT05280067 - Trial result
Breast cancer
BGB-43395 (selective CDK4 inhibitor) + letrozole shows high early ORR with low neutropenia in 1L HR+/HER2− mBC
BGB-43395 is an oral, highly selective CDK4 inhibitor (designed to spare CDK6) combined with the aromatase inhibitor letrozole in an open-label Phase 1a/1b safety-expansion (cohort 2) for CDK4/6i-naive…
NCT06120283 - Trial result
Breast cancer
Vepdegestrant (PROTAC ER degrader) + atirmociclib (selective CDK4 inhibitor) delivers 9–12mo mPFS post-CDK4/6i in ER+/HER2− ABC
Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) designed to degrade estrogen receptor, combined here with atirmociclib (ATI; a selective CDK4 inhibitor) in the open-label, multicenter TACTIVE-K Phase…
NCT06206837 - Trial result
Breast cancer
Atirmociclib (selective CDK4 inhibitor) + letrozole drives 88% Ki-67 CCCA at Day 14 in HR+/HER2− early breast cancer
Atirmociclib (PF-07220060) is an oral, CDK4-selective inhibitor designed to deepen cell-cycle arrest with potentially less dose-limiting toxicity than less-selective CDK4/6 inhibition; in the randomized Phase 2…
NCT06465368 - Trial result
Breast cancer
PLD + Pembrolizumab (Anthracycline/PD-1) Delivers 33% ORR in ER+ MBC
PEG-liposomal doxorubicin (PLD), an anthracycline formulation that may induce immunogenic cell death, was combined with pembrolizumab PD-1 blockade in a Phase 1b trial of ER+/HER2− metastatic breast cancer after…
NCT03591276 - Trial result
Breast cancer
Giredestrant (oral SERD; ER degrader) + palbociclib misses 1L PFS significance vs letrozole + palbociclib in ER+/HER2– mBC
Giredestrant (GIRE) is a next-generation oral selective estrogen receptor antagonist/degrader (SERD) evaluated in the phase III, double-blind persevERA BC trial (NCT04546009) as first-line therapy with palbociclib…
NCT04546009 - Trial result
Breast cancer
Camizestrant (oral SERD/complete ER antagonist) switch at emergent ESR1m extends PFS2 in 1L HR+/HER2− ABC (SERENA-6)
Camizestrant (CAMI) is a next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist tested in the Phase III, ctDNA-guided SERENA-6 switch strategy (NCT04964934): pts with HR+/HER2−…
NCT04964934 - Trial result
Breast cancer
Tucatinib + trastuzumab/pertuzumab extends HER2+ mBC maintenance PFS, but adds liver AEs
Tucatinib is an oral HER2-selective TKI added to trastuzumab + pertuzumab maintenance after taxane + HP induction in HER2-positive metastatic breast cancer, testing whether HER2 blockade can be intensified after…
NCT05132582 - Trial result
Breast cancer
Sacituzumab govitecan (TROP2-directed ADC delivering SN-38) extends PFS2 to 18.2mo vs chemo in 1L PD-(L)1–ineligible mTNBC
Sacituzumab govitecan (SG) is a TROP2-targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor payload SN-38; in the Phase 3 ASCENT-03 trial (NCT05382299), previously untreated metastatic TNBC…
NCT05382299 - Trial result
Breast cancer
Giredestrant (oral SERD/full ER antagonist) + everolimus extends PFS2 and chemo-free survival post-CDK4/6 in ER+ aBC
Giredestrant (GIRE) is an oral selective estrogen receptor degrader (SERD) and full ER antagonist combined with everolimus (E; mTOR inhibitor) in the Phase III evERA Breast Cancer trial (NCT05306340) in ER+, HER2–…
NCT05306340 - New trial
Breast cancer
Phase 2 trastuzumab deruxtecan (HER2 ADC; topoisomerase I payload) + lovastatin (HMG‑CoA inhibitor)
Washington University School of Medicine is running this Phase 2 study testing whether short “priming” with lovastatin—an HMG‑CoA reductase inhibitor used for cholesterol lowering—can modulate membrane biology (via…
NCT07619365 Exploratory - New trial
Breast cancer
Phase 3 RxFINE-Low: ribociclib CDK4/6 inhibitor guided by Oncotype DX genomic risk
This National Cancer Institute–sponsored, randomized Phase 3 trial tests whether patients with high anatomic-stage ER-positive/HER2-negative breast cancer but low genomic recurrence risk (Oncotype DX Recurrence Score…
NCT07391774 Exploratory - New trial
Breast cancer
Phase 1/1b IEV407 trial tests an undisclosed-target agent with endocrine therapy in HR+/HER2- breast cancer.
No disclosed MOA. We do not include details of trials without this basic information.
NCT07604571 First-in-human - New trial Spotlight
Breast cancer
Phase 2 BETTER trial tests pembrolizumab PD-1 blockade with taxane/platinum chemo de-escalation.
MD Anderson Cancer Center is running this Phase 2 neoadjuvant study in high-risk, early-stage triple-negative breast cancer (clinical stage T1cN1-2 or T2-4N0-2) to see whether blood-based ctDNA and breast MRI can…
NCT07610525 Exploratory - New trial
Breast cancer
Phase 1/2 REPEAT tests accelerated partial-breast re-irradiation (aPBI) using external-beam radiation.
Dartmouth-Hitchcock Medical Center is running this prospective Phase 1/2 study to see whether re-irradiating only the partial breast (accelerated partial-breast irradiation, aPBI) yields acceptably low acute toxicity…
NCT07612254 Exploratory - New trial
Breast cancer
Phase 2 elacestrant SERD + trastuzumab/pertuzumab HER2 mAbs in triple-positive breast cancer.
This Phase 2 NYU Langone Health investigator-led study (ELATE; NCT07612215) evaluates the safety and anti-tumor activity of adding elacestrant—an oral selective estrogen receptor degrader (SERD) that binds ER and…
NCT07612215 Exploratory - Trial result Spotlight
Breast cancer
Dato-DXd (TROP2 ADC) + durvalumab (PD-L1) drives ~80% ORR and 14-mo mPFS in 1L metastatic TNBC (BEGONIA)
Dato-DXd is a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload (deruxtecan), combined here with durvalumab (anti–PD-L1) as first-line therapy in unresectable locally…
NCT03742102 - Trial result
Breast cancer
Trastuzumab+pertuzumab dual HER2 blockade with endocrine therapy matches 5-year survival despite lower pCR in HR+/HER2+ eBC
Trastuzumab (HER2 mAb) plus pertuzumab (HER2 dimerization-blocking mAb) were given for 12 weeks neoadjuvantly with either endocrine therapy (ET) or weekly paclitaxel in the randomized Phase II open-label WSG TP-II…
NCT03272477 - New trial
Breast cancer
Early Phase 1 mitazalimab CD40 agonist +/− nivolumab PD-1 inhibitor intratumoral in resectable breast cancer
This early Phase 1 “window-of-opportunity” study tests whether a single intratumoral injection of mitazalimab (a CD40 agonistic monoclonal antibody that activates antigen-presenting cells to enhance T-cell priming)…
NCT07319195 Exploratory - New trial
Breast cancer
Phase 2 bupropion XL norepinephrine–dopamine reuptake inhibitor to improve AI tolerance (HSDD)
University of Illinois at Chicago is running this Phase 2 supportive-care study in women with resected, early-stage hormone receptor–positive breast cancer taking adjuvant aromatase inhibitor (AI) therapy who develop…
NCT07596212 Exploratory - Trial result
Breast cancer
Carboplatin + nivolumab (PD-1) misses primary PFS endpoint in 1L mTNBC, signal in PD-L1+ (SP142 IC≥1%)
Carboplatin plus nivolumab is a platinum chemotherapy + anti–PD-1 checkpoint inhibitor regimen tested vs carboplatin alone in a randomized Phase II first-line metastatic TNBC trial (NCT03414684). In the mITT…
NCT03414684 - Trial result
Breast cancer
SABR (definitive breast RT) + endocrine therapy hits 53% pCR, enabling surgery omission in low-risk HR+ breast cancer
Definitive stereotactic ablative radiotherapy (SABR; 5 fractions) plus endocrine therapy (ET) was tested as a non-operative strategy in a prospective Phase II trial (NCT02945579) for select patients aged ≥40 with…
NCT02945579 - New trial
Breast cancer
Pilot ENDORSE study evaluates response-guided systems medicine report for endocrine-pathway targets (ESR1/PIK3CA/mTOR/HER2)
This pilot, single-arm feasibility study at City of Hope tests whether a biology-guided therapy recommendations report can be delivered on time and be usable in routine decision-making for progressive HR+/HER2-…
NCT07590583 Exploratory - New trial
Breast cancer
Phase 2 NeoTHERa tests HER2 dual-antibody blockade (trastuzumab/pertuzumab) with taxane ± platinum
University of Kansas Medical Center is running this randomized Phase 2 neoadjuvant study in stage II–III HER2-amplified/positive early breast cancer to compare pCR after 6 cycles (every 21 days) of THP vs TCHP before…
NCT07220135 Exploratory - New trial
Breast cancer
Phase 2 inavolisib PI3Kα inhibitor + ribociclib CDK4/6 inhibitor + letrozole in early HR+ breast cancer
This Phase 2, open-label, multicenter neoadjuvant study from Roche/Genentech tests inavolisib-based endocrine combinations in untreated Stage II–IIIC, ER-positive/HER2-negative breast cancer with a tumor PIK3CA…
NCT07054190 Exploratory - Trial result
Breast cancer
ARTEMIS (AC neoadjuvant chemo) links “immune hot/cold” contexture to pCR in early TNBC
ARTEMIS (NCT02276443) tested whether adding a gene-expression molecular classifier could better select early-stage triple-negative breast cancer (TNBC) patients for neoadjuvant doxorubicin/cyclophosphamide (AC)…
NCT02276443 - New trial
Breast cancer
Phase 1b TRICK-NK TROP2-targeted CAR-NK (IL-15 armored, TGFBR2 knockout) + T-DXd
This Phase 1b, open-label dose-escalation then dose-expansion study at MD Anderson tests an allogeneic cord blood–derived NK-cell product engineered with a TROP2-directed CAR plus IL-15 expression (to enhance NK…
NCT07553390 Exploratory - New trial
Breast cancer
Phase 1b/2 PIKTOR (serabelisib PI3Kα inhibitor + sapanisertib dual mTORC1/2 inhibitor)
This Phase 1b/2, multi-center, open-label umbrella study sponsored by Faeth Therapeutics tests “PIKTOR,” an all-oral combination of serabelisib (a PI3K-alpha inhibitor; also referenced as INK-1117 in some materials)…
NCT07558733 Exploratory - New trial
Breast cancer
Phase 2 MO-03 live biotherapeutic (microbiome modulator) plus pembrolizumab PD-1 blockade in early TNBC
This single-group, open-label Phase 2 study tests whether adding MO-03—a live biotherapeutic product intended to modulate the gut microbiome—can improve outcomes when layered onto standard neoadjuvant pembrolizumab…
NCT07552181 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.